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Epilepsy and psychiatric comorbidities are frequently associated, but their common biological substrate is unknown.
We have previously reported altered structural elements and neurotrophins (NTs) expression in mesial temporal
lobe epilepsy (MTLE) patients with psychiatric comorbidities. NTs receptors can regulate neurotransmission and
promote neuroplasticity, being important candidates in the regulation and manifestation of psychopatological
states and seizure-related events. MTLE hippocampi of subjects without psychiatric history, MTLE +major depression,
MTLE + interictal psychosis derived from epilepsy surgery, and control necropsies were investigated for p75NTR, TrkB,
TrkA, and TrkC immunohistochemistry. Increased expression of p75NTR, decreased TrkA, unaltered TrkC, and complex
alterations involving TrkB expression were seen in MTLE groups. Increased TrkB expression in patients without
complete seizure remission and in those with secondarily generalized seizures was seen. Decreased p75NTR expression
associated with interictal psychosis, and increased TrkB in those with psychosis or major depression was also reported,
although their p75NTR/TrkB ratios were lower than in MTLE without psychiatric comorbidities. Our results provide
evidence of alterations in expression of NTs receptors in the epileptogenic hippocampus that are differentially
modulated in presence of psychiatric comorbidities. As already explored in animal models, even in chronic human
MTLE increased TrkB expression, among other NT receptors alterations, may play a major role in seizure type,
frequency and surgery outcome.
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comorbidityIntroduction
Psychiatric comorbidities are frequent in epileptic patients,
although the precise nature of this association is still mat-
ter of debate [1,2]. Mesial temporal lobe epilepsy (MTLE),
the most common cause of intractable epilepsy in adults,
usually shows hippocampal sclerosis (HS), neuronal loss,
gliosis and mossy fiber sprouting [3-6]. We have recently
shown neuropathological data suggesting that there is a* Correspondence: jpleite@fmrp.usp.br
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article, unless otherwise stated.structural basis for psychiatric symptoms in the hippocam-
pus of MTLE patients [7,8], and altered neurotrophin (NT)
expression in presence of psychiatric comorbidities [9].
Hippocampal NTs are upregulated in MTLE patients
[9,10] and in animal models of epilepsy [11-16]. NT recep-
tors have been shown to play important roles in epilepto-
genesis, especially tyrosine receptor kinase B (TrkB) and
p75 neurotrophic receptor (p75NTR) [17-19]. In human
MTLE, a qualitative study performed in the dentate gyrus
and Ammon’s horn showed increased p75NTR expression
in glia and remaining neurons, and few alterations in Trk
expression [20]. In animal models of epilepsy, increased
NT receptors expression has also been related to in-
creased excitability [21-25].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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was reported in the prefrontal cortex [26-28], although
truncated forms of TrkB were elevated [29]. In hippo-
campus, decreased TrkA and TrkB expression has been
documented [27,30], as well as no change in TrkB [31].
Immunolabeling and mRNA levels of TrkA and TrkC
were decreased in the hippocampus of suicide subjects
with major depression when compared to normal subjects
and p75NTR was increased [32]. In post-mortem brain of
teenage suicide victims TrkB mRNA levels were decreased
in both prefrontal cortex and hippocampus [33].
Structural abnormalities, altered neuronal plasticity
and excitability have been described in epilepsy and psy-
chiatric disorders [for review please see [2,34]], and such
features are intrinsically regulated by NTs and their re-
ceptors [35,36]. Here we described NT receptors expres-
sion in subfields of the hippocampus, subicular complex
and entorhinal cortex in a series of MTLE patients with
and without comorbid major depression and interictal
psychosis. Finally, we investigated the possible correl-
ation between NT receptors expression, seizure type and
outcome, and further clinical characteristics.
Materials and methods
Patients
We analyzed the hippocampal formation from MTLE
specimens freshly collected in the operating room and
non-epileptic controls from necropsy, collected between
3.5-6 hours after death. A < 24 h postmortem time limit
allows comparison of necropsy tissue with freshly
collected surgical specimens for their protein levels,
cell morphology and tissue integrity [37,38]. This
study followed the principles of the Declaration of
Helsinki, was registered in Brazilian’s Health Ministry
and was approved by the Research Ethics Committee
of our institution, where this study was performed
(process HCRP #10180/2007). Written informed consent
was obtained from all patients used in this study, and
the Research Ethics Committee also approved the
Consent Term.
MTLE specimens were derived from 40 MTLE pa-
tients who underwent a standard en bloc anterior tem-
poral resection (including 3–4 cm of the hippocampus)
for medically intractable seizures. All had clinical neuro-
pathological confirmation of HS. They were divided into
3 groups: 14 MTLE patients without any history of psy-
chiatric disorder (MTLE group); 13 MTLE patients with
interictal psychosis (MTLE + P group); and 13 MTLE pa-
tients with a diagnosis of major depression (MTLE + D
group). A summary of clinical characteristics of all
groups is depicted in Table 1. According to Blümcke’s
HS categories [39], 17 patients had severe HS, 16 clas-
sical HS, 5 CA1 HS and 2 CA4 HS. No differences were
seen among MTLE groups regarding HS categories (fordetails, please see neuropathological data in Table 2).
For comparison purposes, ten human non-epileptic con-
trol hippocampi from necropsies were processed and
analyzed in the same manner as the surgical cases.
Underlying diseases causing death were cardiomyopathy,
pulmonary infarct or renal-hepatic failure, with no history
of hypoxic episodes during agony, seizures or neurological
diseases. Furthermore, there was no evidence of brain
pathological abnormalities on clinical postmortem exam-
ination of the mesial temporal structures. MTLE and
control specimens were collected between 1996 and
2006. As discussed elsewhere [8], the number of
interictal psychosis cases (n = 13) collected within this
timeframe corresponds to almost the totality of interictal
psychosis cases operated in our Epilepsy Surgery Center
in this same period.
Clinical features of MTLE patients
All patients were referred for pre-surgical assessment
due to drug-resistant seizures as defined in the literature
[40]. Patients were evaluated at the Ribeirao Preto Epilepsy
Surgery Program using standardized protocols approved
by the institution’s Ethics Committee and a written con-
sent form was obtained from each patient. Pre-surgical
investigation at the Epilepsy Monitoring Unit included de-
tailed clinical history, neurological examination, interictal
and ictal scalp/sphenoidal electroencephalography (EEG),
neuropsychology evaluation, and intracarotid amobarbital
memory and language procedure whenever deemed clinic-
ally necessary.
Definition of MTLE followed Engel’s criteria [41]: (I)
Seizure semiology consistent with MTLE, usually with
epigastric/autonomic/psychic auras, followed by com-
plex partial seizures; (II) Pre-surgical investigation con-
firming seizure onset zone in the temporal lobe; (III)
Anterior and mesial temporal interictal spikes on EEG;
(IV) No lesions other than uni- or bilateral hippocampal
atrophy on high resolution magnetic resonance imaging
scans (reduced hippocampal dimensions and increased
T2 signal); (V) Clinical histopathological examination
compatible with HS; (VI) No evidence of dual pathology
identifiable by any of the assessment methods described
(clinical, electrophysiology, neuroimaging and histo-
pathology). Exclusion criteria were: (I) focal neurological
abnormalities on physical examination; (II) generalized
or extra-temporal EEG spikes; (III) marked cognitive im-
pairment indicating dysfunction beyond the temporal
regions.
Information regarding antecedent of an initial precipi-
tant injury, febrile seizures, seizure types, drug regimen
and estimated monthly frequency (within the two years
prior to surgery) were retrospectively collected from
medical records for each patient. Psychiatric evaluations
were conducted in all MTLE patients. Each diagnosis of
Table 1 Demographic and clinical data
MTLE MTLE + D MTLE + P Controls Statistics
Male (n) 8 5 7 4 No difference
Female (n) 6 8 6 6
IPI present (n) 9 8 7 n.a. No difference
IPI absent (n) 5 5 6 n.a.
Febrile seizure present in IPI (n) 5 3 5 n.a. No difference
Febrile seizure absent in IPI (n) 4 3 1 n.a.
Febrile seizure unknown (n) 0 2 1 n.a.
Age of first seizure (years) 3.0 ± 2.3 4.3 ± 5.5 6.8 ± 8.4 n.a. No difference
Age when seizures became recurrent or age of onset (years) 10.2 ± 6.4 13.0 ± 8.1 13.8 ± 8.4 n.a. No difference
Seizure type: CPS (n) 6 1 4 n.a. No differencetr
Seizure type: SGS (n) 8 12 9 n.a.
Seizure frequency (monthly) 12.7 ± 10.1 17.2 ± 15.6 11.7 ± 10.1 n.a. No difference
Right HS (n) 6 7 5 n.a. No difference
Left HS (n) 6 4 6 n.a.
Bilateral HS (n) 2 2 2 n.a.
Right handedness (n) 12 11 13 n.a. No difference
Left handedness (n) 1 2 0 n.a.
Bilateral handedness (n) 1 0 0 n.a.
Memory in verbal tasks: average or above (n) 3 7 2 n.a. No difference
Memory in verbal tasks: below average (n) 11 6 11 n.a.
Memory in non-verbal tasks: average or above (n) 9 7 3 n.a. No differencetr
Memory in non-verbal tasks: below average (n) 5 6 10 n.a.
Full scale IQ 82.2 ± 7.9 84.3 ± 9.6 77.2 ± 7.3 n.a. No difference
Years at school 6.2 ± 3.0 5.1 ± 3.6 4.2 ± 2.6 n.a. No difference
Age at surgery (or at death for controls) (years) 36.1 ± 4.7 37.1 ± 5.4 38.0 ± 6.0 48.1 ± 18.9 No difference
Duration of epilepsy (years) 25.9 ± 6.4 24.1 ± 8.9 24.1 ± 8.6 n.a. No difference
Collected side: right (n) 7 8 6 6 No difference
Collected side: left (n) 7 5 7 4
Collected side: left (n) 7 9 6 4
Surgical outcome: complete remission of seizures (n) 8 2 4 n.a. Fisher’s Exact Test, p = 0.046:
MTLE × MTLE + D
Surgical outcome: only auras and/or fewer seizures (n) 6* 11* 9 n.a.
Values indicated as mean ± std. deviation when applicable. A statistical trend (tr: 0.05 ≤ p ≤ 0.07) was observed suggesting a higher proportion of MTLE + D
patients with SGS than MTLE, and a higher proportion of MTLE + P patients with worse performance in non-verbal memory tasks than MTLE.
*: Two patients in MTLE group; one patient in MTLE + D, and four patients in MTLE + P group presented with auras and seizures post-surgery; the remaining had
only auras, and the proportion was increased in the MTLE + D group. IPI: initial precipitant injury; CPS: complex partial seizure; SGS: secondarily generalized
seizures; HS: hippocampal sclerosis; n.a.: not applicable.
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the presurgical evaluation by two psychiatrists with
experience in psychiatric disorders associated with epi-
lepsy, using the guidelines of the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition. Once a consen-
sus on the classification of psychotic syndromes associated
with epilepsy was lacking at the time of patient evaluation
and tissue collection, and neither DSM-IV nor ICD-10
had addressed this issue specifically [see review in [34]],
the diagnosis of psychosis associated with MTLE was
established according to Sachdev [42], meaning thatpatients with interictal psychosis did not experience
the following: psychotic disorder temporally associated
with seizures, changes in antiepileptic medications, epi-
leptic status, delirium, and psychosis for paradoxical
normalization. This group was defined by a prolonged
psychotic state that was not related to the epileptic sei-
zures. Typically, the psychotic states closely resemble
schizophrenia, with paranoid ideas which might become
systematized, ideas of influence, and auditory hallucina-
tions often of a menacing quality. The points of difference
are: common religious coloring of the paranoid ideas,
Table 2 Summary of neuropathological data
MTLE MTLE + D MTLE + P Controls
Neuronal density (#/mm3 × 103)
Granular layer 87.1 ± 30.5 87.7 ± 36.6 89.9 ± 34.0 171.5 ± 39.5
Hilus 4.8 ± 3.4 5.1 ± 4.3 5.6 ± 3.9 13.9 ± 5.9
CA4 10.6 ± 7.9 8.8 ± 7.5 7.9 ± 4.1 23.6 ± 8.2
CA3 15.1 ± 10.5 11.7 ± 9.4 14.8 ± 8.9 22.9 ± 6.4
CA2 17.7 ± 10.3 15.9 ± 5.4 11.9 ± 5.8 22.8 ± 8.2
CA1 7.9 ± 5.4 3.7 ± 2.5 2.9 ± 2.4 18.3 ± 8.1
Prosubiculum 11.4 ± 6.1 7.8 ± 4.2 6.2 ± 4.0 23.7 ± 6.2
Subiculum 21.5 ± 9.7 20.0 ± 12.6 16.0 ± 10.6 17.6 ± 7.4
Parasubiculum 17.3 ± 8.1 14.9 ± 8.3 15.3 ± 8.3 17.3 ± 5.6
Entorhinal cortex 27.4 ± 11.3 20.0 ± 8.5 20.8 ± 5.8 38.6 ± 8.6
HS classification (n)
Severe HS 7 5 5 n.a.
Classical HS 5 6 5 n.a.
CA1 HS 1 2 2 n.a.
CA4 HS 1 0 1 n.a.
p75NTR IR area (μm2 × 102)
Granular layer 3974.2 ± 1425.8 2945.2 ± 1254.1 3064.6 ± 1135.7 1586.7 ± 623.4
Hilus 1961.7 ± 585.5 1708.5 ± 532.3 1721.9 ± 558.6 1115.7 ± 359.1
CA4 2570.1 ± 743.2 1853.3 ± 702.5 2350.2 ± 619.5 1224.4 ± 418.1
CA3 2950.6 ± 693.7 3816.7 ± 1342.0 2756.6 ± 791.6 1964.5 ± 786.6
CA2 4189.7 ± 924.4 3817.4 ± 1085.0 3598.5 ± 726.5 2242.7 ± 910.7
CA1 2941.2 ± 916.4 2660.8 ± 663.0 2583.7 ± 260.7 1572.0 ± 692.3
Prosubiculum 2747.7 ± 896.4 2243.4 ± 568.8 2278.7 ± 529.2 1652.9 ± 810.6
Subiculum 3372.1 ± 1178.8 2549.5 ± 717.1 2342.2 ± 726.0 1275.5 ± 567.6
Parasubiculum 3752.4 ± 1026.5 3349.3 ± 916.4 2704.0 ± 497.6 1397.5 ± 580.2
Entorhinal cortex 3303.6 ± 564.7 3044.3 ± 552.3 3436.0 ± 536.8 1265.0 ± 622.2
TrkB IR area (μm2 × 102)
Granular layer 1970.3 ± 651.6 3883.8 ± 1442.6 4307.5 ± 1039.8 2591.0 ± 539.0
Hilus 1490.4 ± 551.2 2214.4 ± 712.8 2693.6 ± 838.0 1937.9 ± 510.2
CA4 1369.0 ± 602.3 2590.7 ± 1105.6 2861.6 ± 458.0 2911.2 ± 839.6
CA3 1857.9 ± 436.3 2124.1 ± 703.8 3050.8 ± 646.0 3892.2 ± 958.6
CA2 2311.3 ± 700.8 3276.0 ± 1078.4 3182.0 ± 593.3 3732.2 ± 956.4
CA1 1513.3 ± 442.5 1729.8 ± 540.6 1931.2 ± 596.6 2888.2 ± 585.8
Prosubiculum 1454.7 ± 445.4 1427.5 ± 434.1 2224.4 ± 679.7 2694.9 ± 956.7
Subiculum 1649.9 ± 415.1 2776.0 ± 806.4 2843.5 ± 977.7 2531.9 ± 622.9
Parasubiculum 1689.4 ± 425.3 2833.3 ± 499.8 2778.9 ± 412.3 3000.3 ± 1086.8
Entorhinal cortex 1893.1 ± 302.0 2808.3 ± 509.2 2870.6 ± 588.5 2930.0 ± 857.8
TrkA IR area (μm2 × 102)
Granular layer 1757.7 ± 646.3 2155.8 ± 721.3 1444.2 ± 289.9 2181.6 ± 889.4
Hilus 1213.1 ± 549.7 1252.2 ± 479.1 1183.7 ± 378.9 1960.9 ± 716.8
CA4 1441.1 ± 553.3 1441.1 ± 470.7 1322.1 ± 291.9 1802.1 ± 570.2
CA3 1473.9 ± 333.1 1643.2 ± 487.0 1193.3 ± 267.3 2614.6 ± 918.1
CA2 1820.7 ± 587.9 2097.6 ± 607.7 1675.1 ± 421.3 2463.7 ± 768.1
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Table 2 Summary of neuropathological data (Continued)
CA1 1157.7 ± 350.1 1042.9 ± 291.3 1179.6 ± 462.2 2169.7 ± 637.2
Prosubiculum 1202.9 ± 345.8 1017.0 ± 380.5 1279.3 ± 295.0 1888.3 ± 566.8
Subiculum 1515.8 ± 360.7 1662.1 ± 456.6 1456.9 ± 375.2 1780.5 ± 555.8
Parasubiculum 1733.4 ± 391.2 1524.4 ± 252.6 1572.3 ± 391.2 1834.7 ± 600.3
Entorhinal cortex 1779.4 ± 641.3 1135.7 ± 429.9 1464.5 ± 295.9 1693.8 ± 383.6
TrkC IR area (μm2 × 102)
Granular layer 1295.3 ± 416.3 1194.4 ± 402.4 1106.0 ± 300.0 1103.5 ± 477.8
Hilus 1120.3 ± 313.4 1114.3 ± 303.8 1076.2 ± 411.7 1427.1 ± 395.4
CA4 1188.5 ± 297.0 1270.0 ± 483.5 1387.8 ± 468.6 1316.9 ± 184.6
CA3 1512.1 ± 425.0 1333.3 ± 787.3 1742.3 ± 608.3 2323.6 ± 772.3
CA2 2076.8 ± 485.9 1630.9 ± 473.3 1808.3 ± 859.2 2012.1 ± 789.9
CA1 1133.3 ± 378.9 1284.6 ± 432.1 1069.6 ± 415.5 1092.8 ± 313.6
Prosubiculum 1200.4 ± 193.7 1069.7 ± 336.3 1083.7 ± 404.3 1117.1 ± 634.2
Subiculum 1261.1 ± 361.2 1158.1 ± 308.1 1172.9 ± 468.8 942.9 ± 154.2
Parasubiculum 1375.7 ± 306.1 1282.1 ± 385.6 1155.6 ± 453.2 1204.2 ± 538.7
Entorhinal cortex 1610.7 ± 438.8 1523.6 ± 522.5 1535.5 ± 598.0 958.1 ± 399.1
Values indicated as mean ± std. deviation or as number of patients (n), when indicated. n.a.: not applicable.
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and no typical deterioration to the hebephrenic state [43].
Patients had no history of previous psychiatric disorders
(prior to seizure onset) or of substance dependence at any
time. Global IQ was calculated after neuropsychological
tests (complete WAIS-III or WAIS-R protocol).
Tissue collection and immunohistochemical processing
Hippocampal body specimens were segmented into 1 cm
blocks transversely oriented to the hippocampal long axis
and were placed in buffered paraformaldehyde (Sigma, St
Louis, MO, USA). After 48–96 hours specimens were proc-
essed and paraffin embedded for immunohistochemistry.
Immunohistochemistry was performed with antibodies
that identified immunoreactivity for Neu-N, a nuclear
protein found in the nuclei of mature neurons (1:1000
dilution; Chemicon-Millipore, Billerica, MA, USA), and
for the NT receptors: p75NTR, TrkB, TrkA and TrkC (all
diluted 1:30; Santa Cruz Biotechnology, Santa Cruz, CA,
USA). According to the manufacturers and as already
verified in selected references [18,44-48], these anti-
bodies recognize a single band in western blot and show
no cross-reactivity with other NT receptors. Briefly, par-
affin embedded MTLE and control hippocampi were
processed together for each antibody as described in
Kandratavicius et al. [7], with overnight incubation at
room temperature and developed simultaneously for
10 min in 0.05% 3,3’-diaminobenzidine tetrahydrochloride
(Pierce, Rockford, USA) and 0.01% hydrogen peroxide
(Merck, Darmstadt, Germany). After sufficient colori-
zation, reaction was halted by washing in several rinses of
distilled water, dehydrated through graded ethanol toxylene (Merck, Darmstadt, Germany), and cover slipped
with Krystalon (EM Science, Gibbstown, NJ, USA). Adja-
cent sections were hematoxilin-eosin stained and examined
for tissue integrity. Control sections without the primary
antisera did not reveal staining (data not shown).
Cell count
Neuronal counting for MTLE and control hippocampi
was performed based on Lorente de No’s classification
[49], including fascia dentata granular and subgranular
cells, polymorphic hilar neurons (limited to a region
between stratum granulosum and CA4 pyramidal cells,
being at least 50 μm from the stratum granulosum and
100 μm from CA4), as well as pyramidal cells in CA4
(the portion of Ammon’s horn that permeates the inner
part of the dentate gyrus), CA3, CA2, CA1, prosubiculum,
subiculum, parasubiculum, and entorhinal cortex layer III.
Cell densities (neurons per cubic millimeter) were esti-
mated in 8 μm Neu-N stained slices at 400x magnification
with a morphometric grid methodology using Abercrom-
bie’s correction [50] as previously described and well
established in the literature for surgical hippocampal frag-
ments [3,5-7,51-55].
Semi-quantitative analysis of immunohistochemistry
Adjacent slides to those examined for neuronal density
were analyzed for NT receptors expression. In brief, all
digitized images were analyzed with Image J software,
following the same criteria: (I) the software identifies the
gray value distribution of a subfield’s digital image (total
area image for each subfield = 313.7 μm × 235.3 μm);
(II) the immunoreactive (IR) area is selected (i.e. positive
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threshold range is pre-settled based on control group sec-
tions, to exclude the low intensity gray value of back-
ground staining from the analysis. A similar approach was
used by our group elsewhere [6]. Results for granular layer
included granular cell layer per se and proximal molecular
layer. Analyses were conducted by one investigator (LK),
blind to hippocampal pathology and group classification.
Data analysis
Data were analyzed using the statistical program PAWS
(version 18.0) and SigmaPlot (version 11.0). Groups were
compared using analysis of variance (ANOVA one way,
with Bonferroni post-hoc test) or unpaired t test for vari-
ables with normal distribution, and Kruskal-Wallis One
Way Analysis of Variance on Ranks (with Dunn post hoc
test) or Mann–Whitney Rank Sum Test for variables
without normal distribution. Fisher Exact test was applied
for comparison of relative frequencies of clinical variables
between groups. Other statistical tests included two-way
ANOVA with Holm-Sidak post-hoc test, Pearson correl-
ation analyses and analysis of covariance (ANCOVA).
Statistical significance was set at p < 0.05 and values pre-
sented as mean ± SD. Depicted p values in all ANOVA
analysis refer to p values after post-hoc tests.
Results
Clinical profiles
The four patients groups did not show significant differ-
ences in gender, age or collected side (Table 1). Clinical
variables such as presence of an initial precipitant injury
and febrile seizures, age of first seizure and seizure on-
set, seizure frequency and epilepsy duration, HS side,
handedness, IQ, years at school and performance in ver-
bal memory tests were homogeneously distributed
among MTLE groups. MTLE + D patients exhibited a
trend (0.05 ≤ p ≤ 0.07) to increased proportion of patients
with secondarily generalized seizures (SGS) when com-
pared to patients without psychiatric comorbidities, and
MTLE + P patients exhibited a trend to worse perform-
ance in non-verbal memory tasks.
Two patients in MTLE group, one patient in MTLE +
D, and four patients in MTLE + P group presented with
auras and seizures post-surgery, although frequency was
decreased if compared with pre-surgery period. The re-
maining of patients without complete remission had only
auras, and the proportion of patients with this outcome
was higher in the group with history of major depression
when compared to MTLE without psychiatric comorbidi-
ties (Fisher’s Exact Test, p = 0.046).
All epileptic patients were on antiepileptic drugs (carba-
mazepine, oxcarbazepine, phenobarbital, and/or phenytoin).
In addition, patients were also taking benzodiazepines
(MTLE group: 8 of 14; MTLE +D: 10 of 13; MTLE + Pgroup 10 of 13), fluoxetine (MTLE +D: 4 of 13) and halo-
peridol (MTLE + P group: 10 of 13). No differences in
neuronal density, or NT receptors expression were seen
between patients taking or not taking benzodiazepines.
No differences in neuropsychological tests between pa-
tients taking or not taking benzodiazepines, fluoxetine or
haloperidol were seen. Possible influence of fluoxetine and
haloperidol in NT receptors expression will be explored
on the next sections.
Neuropathological characterization: neuronal density
Evaluation of epileptogenic and control hippocampal for-
mation showed reduced neuron density in the granular
layer, hilus, CA4, CA1 and prosubiculum of all MTLE
groups when compared to control (Figure 1, asterisks). In
addition, we found significant neuron density reduction in
the entorhinal cortex of MTLE patients with major depres-
sion and interictal psychosis when compared to controls
and a trend to decreased neuronal density in CA2 of
MTLE + P specimens. More details on neuronal density
and its relation with clinical features can be found in our
previous study on NTs expression [9], since we used here
the same specimens’ series. Results of neuronal densities
were showed here again because given the differences
among the groups, an important question was whether the
statistical differences in NT receptors expression for the
four groups could be accounted for by changes in neuronal
densities. We therefore performed an analysis of covari-
ance (ANCOVA) comparing groups and neuronal densities
with NT receptors IR area and the results are shown in
Table 3. As depicted, difference between groups in NT re-
ceptors expression remained significant in all subfields for
TrkB, five subfields for p75NTR and two subfields for TrkA
after cell count correction (Table 3, boldfaced values).
These results indicate that the groups showed significant
differences in NT receptors expression levels that were not
influenced by changes in neuronal densities.
NT receptors expression
Strong p75NTR immunoreactivity was detected in all hip-
pocampal formation subfields (Figure 2, a-t). In MTLE
specimens, glial staining was evident, while in controls
only neurons were immunoreactive (IR). In subiculum,
increased staining was seen in MTLE specimens, and less
in MTLE with psychosis and controls (Figure 3, a-d).
p75NTR IR area was lower in controls (Figure 3e, asterisks)
and independent of neuronal density in CA4, CA1, subi-
culum, parasubiculum and entorhinal cortex (Table 3).
Among MTLE groups, patients with interictal psychosis
showed decreased p75NTR expression in subiculum and
parasubiculum (Figure 3e, hash signs).
Patients with SGS showed decreased p75NTR expres-
sion in all hippocampal formation subfields when com-
pared to those with complex partial seizures (CPS), and
Figure 1 Neuronal density in human hippocampal formation subfields. Neuronal density values from MTLE (black bars), MTLE + D
(gray bars), MTLE + P (light gray bars) and from non-epileptic controls (white bars) are indicated as mean ± std. deviation. Double asterisk indicate
significant statistical difference (p < 0.001) between epileptics and control group. Neuronal loss was observed in the granular layer, hilus, CA4,
CA1, prosubiculum and entorhinal cortex. A statistical trend (tr: 0.05≤ p≤ 0.07) to decreased neuronal density in MTLE + P CA2 when compared
to control can also be seen.
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layer (SGS: 3030.8 ± 1232.7 × 102 μm2 versus CPS: 4200.1 ±
1271.1 × 102 μm2, t (38) = 2.51, p = 0.02), CA4 (SGS:
2073.3 ± 693.0 × 102 μm2 versus CPS: 2723.7 ± 664.9 ×
102 μm2, t (35) = 2.25, p = 0.03), and CA2 (SGS: 3611.0 ±
833.5 × 102 μm2 versus CPS: 4631.6 ± 725.9 × 102 μm2,Table 3 Analysis of Covariance (ANCOVA) comparing patients
receptors IR area





















Data are presented as F values/p values, and significant results are indicated in boldt (32) = 2.82, p = 0.01). No interaction between psychi-
atric status and seizure type was seen (p = 0.875). No ef-
fects of fluoxetine or haloperidol were seen on p75NTR
expression.
TrkB expression in neurons and dendritic processes was
detected in all subfields of the hippocampal formation’ categories and neuronal density (counts), with NT












Figure 2 p75NTR expression in the human hippocampal formation. Increased expression can be seen in MTLE neurons and glial-like cells,
while in control only neurons are stained. GL: granular layer; HIL: hilus; PRO: prosubiculum; SUB: subiculum; PAR: parasubiculum; ENT: entorhinal
cortex. Scale bar (a-t): 50 μm.
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http://www.actaneurocomms.org/content/2/1/81(Figure 4, a-s). In CA3, increased TrkB IR was seen in
MTLE + P and controls when compared to MTLE and
MTLE +D (Figure 5, a-d). Among MTLE groups, MTLE
without psychiatric comorbidities showed consistently
lower TrkB expression (Figure 5e, hash signs), with excep-
tion of CA2 and CA1, where differences did not reach
statistical significance. In the granular layer, CA4, subicu-
lum, parasubiculum and entorhinal cortex both MTLE +
D and MTLE + P presented with increased TrkB expres-
sion when compared to MTLE without psychiatric comor-
bidities. Controls showed higher TrkB expression than
MTLE in the entire Ammon’s horn, prosubiculum, para-
subiculum and entorhinal cortex (Figure 5e, asterisks).
Interestingly, TrkB expression in patients with SGS
was higher than in patients with CPS in all hippocampal
formation subfields, being statistically significant in CA4
(SGS: 2487.0 ± 961.9 × 102 μm2 versus CPS: 1640.5 ±
835.7 × 102 μm2, t (35) = −2.29, p = 0.03). No interaction
between psychiatric status and seizure type was seen
(p = 0.711) suggesting that increased TrkB expression
levels seen in specimens from patients with a psychiatric
diagnosis as well as on those with SGS are independent
findings. Moreover, complete seizure remission post-sur-
gery was achieved by the ones with lower hippocampal
TrkB expression. Difference between groups was signi-
ficant in the granular layer (Remission: 2768.2 ± 1086.5 ×
102 μm2 versus No-remission: 4418.1 ± 1864.7 × 102 μm2,
t (38) = 2.89, p = 0.008) and prosubiculum (Remission:1533.1 ± 456.0 × 102 μm2 versus No-remission: 2179.9 ±
688.4 × 102 μm2, t (36) = 2.61, p = 0.02). Psychiatric status
and seizure outcome exhibited a significant interaction
(p = 0.016), probably due to an increased proportion of
patients without complete seizure remission and with a
psychiatric diagnosis. In fact, differences in TrkB expres-
sion between remission versus no-remission patients
were evident in MTLE with psychiatric comorbidities
(p < 0.007) but not on those without psychiatric comor-
bidities (p = 0.717). Also, a trend to a direct correlation
between seizure frequency and TrkB expression in the
granular layer was noted (Pearson’s R = +0.35, p = 0.05).
No effects of fluoxetine or haloperidol were seen on TrkB
expression.
TrkA expression was predominantly neuronal (Figure 6,
a-d) and decreased in epileptic groups when compared
to controls in the hilus, CA3, CA1 and prosubiculum
(Figure 6e, asterisks). When corrected for neuronal den-
sities differences between MTLE groups and control, CA1
and prosubiculum remained significant (Table 3). No
differences among MTLE groups or in seizure type and
outcome were seen regarding TrkA levels. In MTLE +D
group, patients taking fluoxetine showed increased TrkA
expression in CA4 (1804.1 ± 366.8 × 102 μm2 versus
1088.8 ± 309.6 × 102 μm2, t (10) = 2.81, p = 0.04) and CA2
(2601.7 ± 583.0 × 102 μm2 versus 1719.5 ± 259.2 × 102 μm2,
t (9) = 2.75, p = 0.04). In MTLE + P group, patients taking
haloperidol showed decreased TrkA expression in CA4
Figure 3 p75NTR expression in MTLE specimens with and without psychiatric comorbidities and in non-epileptic controls. MTLE
subiculum (a) exhibited increased p75NTR expression when compared to MTLE + D (b), MTLE + P (c) and control group (d). We found p75NTR
immunoreactive area values (e) higher epileptic groups than in controls (double asterisk, p < 0.01; single asterisk, p < 0.05), and differences among
MTLE groups (single hash sign, p < 0.05). Values from MTLE (black bars), MTLE + D (gray bars), MTLE + P (light gray bars) and from non-epileptic
controls (white bars) are indicated as mean ± std. deviation. Scale bar (a-d): 50 μm.
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t (11) = −4.36, p = 0.003).
TrkC expression was also predominantly neuronal
(Figure 7, a-d) but no differences among groups were
found (Figure 7e). In MTLE + D group, patients taking
fluoxetine showed increased TrkC expression in CA4
(1741.8 ± 88.7 × 102 μm2 versus 1034.0 ± 405.3 × 102 μm2,
t (11) = 3.51, p = 0.03). In order to examine whether there
was an imbalance in the expression of TrkA, B, and C in
relation to p75NTR expression, we determined the expres-
sion ratios of p75NTR versus TrkA, TrkB, and TrkC. As
shown in Table 4, we observed significant increase in
expression ratios of p75NTR versus TrkA in all subfields
except CA3 and prosubiculum. p75NTR/TrkB ratios wereelevated in all hippocampal formation subfields of epi-
leptogenic hippocampus when compared to controls. Be-
sides, differences among MTLE groups were also detected
in all subfields except CA3, CA2 and CA1, with decreased
p75NTR/TrkB ratio in MTLE with psychiatric comorbi-
dities. Imbalance in the expression of TrkB in relation to
p75NTR expression may also play a role in seizure type
since patients with SGS showed decreased p75NTR/TrkB
ratio when compared to those with CPS. Difference be-
tween groups was significant in the granular layer (SGS:
1.13 ± 0.75 versus CPS: 1.86 ± 1.07, t (38) = 2.25, p = 0.03),
CA4 (SGS: 0.98 ± 0.51 versus CPS: 2.13 ± 1.13, t (35) =
2.59, p = 0.02), CA1 (SGS: 1.55 ± 0.50 versus CPS: 2.31 ±
0.78, t (36) = 3.11, p = 0.005), and prosubiculum (SGS:
Figure 4 TrkB expression in the human hippocampal formation. Predominant neuronal expression can be seen in all subfields. Apical
dendrites were also evident in MTLE and controls. GL: granular layer; HIL: hilus; PRO: prosubiculum; SUB: subiculum; PAR: parasubiculum; ENT:
entorhinal cortex. Scale bar (a-t): 50 μm.
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http://www.actaneurocomms.org/content/2/1/811.34 ± 0.48 versus CPS: 1.90 ± 0.59, t (36) = 2.54, p = 0.02).
No interaction between psychiatric status and seizure type
was seen (p = 0.867), suggesting that decreased p75/TrkB
ratio levels detected in specimens from patients with a
psychiatric diagnosis as well as on those with SGS are
independent findings. Expression ratios of p75NTR to
TrkC were increased in MTLE patients when compared
to controls in the dentate gyrus, CA3, CA2, parasubicu-
lum and entorhinal cortex.
Discussion
In the present study, we found in the epileptogenic hip-
pocampal formation increased expression of p75NTR,
decreased TrkA expression, and complex alterations in-
volving TrkB expression. Increased TrkB expression in
patients without complete seizure remission and in those
with SGS, and a trend to a direct correlation between
TrkB and seizure frequency was seen. In addition, de-
creased p75NTR expression associated with interictal
psychosis, and increased TrkB in those with psychosis
or major depression was also reported, although their
p75NTR/TrkB ratios were lower than in MTLE without
psychiatric comorbidities.
There are scarce reports on hippocampal NT receptors
expression in schizophrenia and mood disorders, showing
unaltered, decreased and increased levels [31,56,57]. Since
our series refers to psychiatric states comorbid with epi-
lepsy, our discussion will focus mainly in NT receptorsexpression considering whenever possible evidences found
in epilepsy. In our earlier study [9], we found increased
nerve growth factor (NGF) and brain derived neurotro-
phic factor (BDNF) expression in MTLE, and decreased
NGF and BDNF in specific hippocampal subfields of
MTLE + P, but increased NGF in the granular layer of
MTLE +D. Those previous and the present results can be
directly correlated since they are from the same patient’s
series. In MTLE and MTLE +D, a decrease in TrkA might
represent a compensatory effect to increased NGF. Since
in MTLE + P both NGF and TrkA are in low levels, we
could expect a diminished trophic tone, for instance, in
mossy fiber sprouting, as we indeed noticed in previous
studies [7,9]. BDNF was also decreased in MTLE + P
granular layer [9], but its high affinity ligand TrkB was
increased. Here we must emphasize the relevance of
our expression ratios’ findings between p75NTR and
Trks. The low affinity NT receptor p75NTR may have a
pro-apoptotic role when acting without Trks and/or as a
ligand for pro-NTs; and p75NTR may have an anti-apop-
totic role, strengthening mature NT biding and signal
transduction when forming a complex with Trks [58].
Coexpression of p75NTR and Trks has been previously
demonstrated with immunofluorescence in hippocampal
sclerosis [20], and a way to quantitatively express this rela-
tion is by examining p75NTR and Trks expression ratios,
as explored by Dwivedi et al. [32]. Increased p75NTR/Trks
ratios in most hippocampal subfields of MTLE specimens
Figure 5 TrkB expression in MTLE specimens with and without psychiatric comorbidities and in non-epileptic controls. MTLE (a) and
MTLE + D (c) exhibited decreased TrkB expression in CA3 when compared to MTLE + P (b) and control group (d). We found TrkB immunoreactive
area values (e) higher in the dentate gyrus of epileptic groups with psychiatric comorbidities, and decreased in other subfields of MTLE
specimens when compared to controls (double asterisk, p < 0.01; single asterisk, p < 0.05). Differences among epileptic groups were seen in the
granular layer, hilus, CA4, CA3, prosubiculum, subiculum, parasubiculum and entorhinal cortex, where MTLE specimens showed decreased TrkB
expression when compared to MTLE with psychiatric comorbidities (single hash sign, p < 0.05; double hash sign, p < 0.01). Values from MTLE
(black bars), MTLE + D (gray bars), MTLE + P (light gray bars) and from non-epileptic controls (white bars) are indicated as mean ± std. deviation.
Scale bar (a-d): 50 μm.
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ment of the efficacy of synaptic neurotransmission, but
decreased p75NTR/TrkB ratios in MTLE with psychiatric
comorbidities could be associated with structural abnor-
malities and reduced neuronal plasticity in these hippo-
campi. In fact, significant neuronal loss in the entorhinal
cortex and a trend in CA2 were seen only in specimens
with major depression and/or psychosis.
In schizophrenia, decreased expression of TrkB in the
prefrontal cortex may contribute to reduced BDNF-TrkB
signaling and lead to reduced neuronal plasticity [26,29].
In our previous study [9] we hypothesized that given thereciprocal BDNF/glutamate modulation [59], normaliza-
tion of low BDNF levels found in interictal psychosis [9]
would help to reestablish the balance in a possible situation
of glutamatergic hypofunction. As reviewed by Schuman
[60], TrkB signaling becomes readily desensitized after
binding BDNF. Thus, BDNF-TrkB signaling could be
potentiated in presence of increased TrkB availability, as
it seems to occur in MTLE + P. Together with the already
increased BDNF baseline expression found in epilepsy, a
comorbid psychotic state would display milder symptoms
than in schizophrenia, as it is indeed depicted in interictal
psychosis [43]. In major depression we found equally
Figure 6 TrkA expression in MTLE specimens with and without psychiatric comorbidities and in non-epileptic controls. MTLE (a),
MTLE + D (b) and MTLE + P (c) exhibited decreased TrkA expression in CA3 when compared to control group (d). We found TrkA immunoreactive
area values (e) lower in the hilus, CA3, CA1 and prosubiculum of epileptic groups when compared to controls (double asterisk, p < 0.01; single asterisk,
p < 0.05). Values from MTLE (black bars), MTLE + D (gray bars), MTLE + P (light gray bars) and from non-epileptic controls (white bars) are indicated as
mean ± std. deviation. Scale bar (a-d): 50 μm.
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another study showed that NT receptors expression levels
were not different between suicide subjects with major
depression or with a history of other psychiatric disorders
[32]. Although increased TrkB expression in MTLE +D
could be an effect of antidepressant drug exposure as
extensively documented in the literature [61,62], in our
series we found an effect of fluoxetine only on TrkA and
TrkC expression. Brain specimens of patients with schizo-
phrenia and major depression usually show decreased
TrkB expression, although there are also findings of
unaltered levels [31,63]. Our results have indicated that
increased TrkB expression in hippocampal specimens of
MTLE with psychiatric comorbidities and in those withSGS are independent findings, and we should reemphasize
that we are examining psychiatric states secondary to epi-
lepsy. Therefore, if TrkB is intrinsically related to hyperex-
citability, epileptogenesis and seizures [19,64], a comorbid
psychiatric condition in epilepsy could display a different
pattern of expression when compared to the pure forms
of the psychopathologies, as we found in our results.
Glial expression of p75NTR was detected in MTLE
groups, as already described in human MTLE [20] and
in seizure models [65]. While in hippocampal neurons
NGF binding to p75NTR results in apoptosis [66], in glial
cells the signal may serve as a negative modulator to
restrict its proliferation [65]. If there is a differential glial
expression and activation in MTLE with and without
Figure 7 TrkC expression in MTLE specimens with and without psychiatric comorbidities and in non-epileptic controls. MTLE (a) and
MTLE + D (b), MTLE + P (c) and control group (d) exhibited predominatly neuronal TrkC expression in CA3. No statistical differences in TrkC
immunoreactive area were found among groups (e). Values from MTLE (black bars), MTLE + D (gray bars), MTLE + P (light gray bars) and from
non-epileptic controls (white bars) are indicated as mean ± std. deviation. Scale bar (a-d): 50 μm.
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sion results, it needs to be further clarified.
Just recently the clinical correlates of SGS in temporal
lobe epilepsy were described. Bone et al. [67] reported a
positive association between the presence of hippocampal
sclerosis and SGS, which is in agreement with the high
proportion of patients with SGS in our series. Never-
theless, SGSs are not uniform entities [68], and the patho-
physiology of secondary generalization is still poorly
understood. We found that patients with SGS showed
increased TrkB expression, decreased p75NTR/TrkB ratio,
and decreased p75NTR expression when compared to those
with CPS. Also, there was a trend to a direct correlation
between seizure frequency and TrkB expression. Theclose relationship of TrkB and epileptogenesis has
been explored in animal models for more than a decade
[17,19,22,23,69,70], and TrkB acts as an indispensable
molecule for seizure generation and epilepsy development.
Here we described for the first time in human MTLE that
even in a chronic scenario TrkB may play a major role on
seizure type and epilepsy surgery outcome. Regarding
lower p75NTR levels found in SGS it is useful to recollect
that we found decreased NGF in those same specimens
[9]. In the kindling model, when a synthetic peptide is
used to interfere with NGF binding to TrkA and p75NTR
receptors, the kindling process is suppressed [21]. In fact,
when NGF is not able to properly interact with their
receptors, seizure development is halted [71]. In chronic
Table 4 Ratios of p75NTR/Trks in hippocampal subfields of MTLE groups and normal controls
MTLE MTLE + D MTLE + P Controls p value
TrkA
Granular layer 2.4 ± 1.1 1.4 ± 0.4 2.1 ± 1.4 1.0 ± 0.5 0.04 (MTLE × CTRL)
Hilus 2.3 ± 2.0 1.4 ± 0.5 1.5 ± 0.5 0.8 ± 0.4 0.04 (MTLE × CTRL)
CA4 1.9 ± 0.8 1.4 ± 0.4 1.9 ± 0.6 0.9 ± 0.3 0.04 (MTLE and MTLE + P × CTRL)
CA3 1.9 ± 1.0 2.3 ± 0.9 2.6 ± 1.0 1.1 ± 0.6 n.s.
CA2 2.6 ± 1.2 1.7 ± 0.5 2.1 ± 0.6 1.1 ± 0.6 0.04 (MTLE x CTRL)
CA1 2.6 ± 1.4 2.6 ± 0.9 2.3 ± 1.1 0.9 ± 0.5 0.04 (MTLE and MTLE + D × CTRL)
Prosubiculum 2.1 ± 1.2 2.1 ± 1.0 1.9 ± 0.3 1.0 ± 0.4 n.s.
Subiculum 2.3 ± 1.0 1.5 ± 0.5 1.8 ± 0.6 0.9 ± 0.5 0.005 (MTLE x CTRL)
Parasubiculum 2.2 ± 0.6 2.3 ± 0.6 1.8 ± 0.4 1.1 ± 0.5 0.004 (MTLE and MTLE + D × CTRL)
Entorhinal cortex 2.3 ± 0.8 3.5 ± 2.1 2.4 ± 1.0 0.9 ± 0.4 0.02 (MTLE + D × CTRL)
TrkB
Granular layer 2.2 ± 0.9 0.9 ± 0.5 0.8 ± 0.5 0.6 ± 0.2 <0.0001 (MTLE × all groups)
Hilus 1.6 ± 1.1 0.9 ± 0.4 0.7 ± 0.2 0.6 ± 0.1 0.01 (MTLE × MTLE + P); 0.02 (MTLE × CTRL)
CA4 2.1 ± 1.0 0.9 ± 0.4 0.8 ± 0.2 0.5 ± 0.1 <0.003 (MTLE × all groups)
CA3 1.7 ± 0.9 2.0 ± 1.0 1.0 ± 0.4 0.6 ± 0.2 0.04 (MTLE and MTLE + D × CTRL)
CA2 2.1 ± 1.3 1.3 ± 0.4 1.1 ± 0.2 0.6 ± 0.1 0.01 (MTLE × CTRL)
CA1 2.1 ± 0.8 1.5 ± 0.4 1.5 ± 0.5 0.6 ± 0.2 <0.0001 (MTLE × CTRL)
Prosubiculum 2.1 ± 0.5 1.4 ± 0.4 1.2 ± 0.3 0.7 ± 0.1 <0.01 (MTLE × all groups); 0.03 (MTLE + D × CTRL)
Subiculum 2.1 ± 0.8 1.0 ± 0.4 0.9 ± 0.3 0.6 ± 0.3 <0.0001 (MTLE × all groups)
Parasubiculum 2.3 ± 0.7 1.2 ± 0.4 1.0 ± 0.2 0.6 ± 0.2 <0.0001 (MTLE × all groups)
Entorhinal cortex 1.9 ± 0.4 1.1 ± 0.4 1.3 ± 0.4 0.5 ± 0.1 0.01 (MTLE × MTLE + D); <0.01 (MTLE groups × CTRL)
TrkC
Granular layer 3.4 ± 1.7 3.0 ± 1.1 2.9 ± 1.2 1.6 ± 0.7 <0.01 (MTLE groups × CTRL)
Hilus 2.0 ± 1.0 1.5 ± 0.5 1.6 ± 0.3 0.8 ± 0.2 0.009 (MTLE × CTRL)
CA4 2.3 ± 1.2 1.6 ± 0.6 1.7 ± 0.6 1.0 ± 0.4 n.s.
CA3 2.0 ± 0.7 2.4 ± 0.4 1.7 ± 0.4 1.1 ± 0.5 <0.01 (MTLE and MTLE + D × CTRL)
CA2 2.2 ± 0.8 2.4 ± 0.4 1.7 ± 0.4 1.1 ± 0.5 0.02 (MTLE and MTLE + D × CTRL)
CA1 2.9 ± 1.3 2.7 ± 1.8 2.4 ± 0.7 1.3 ± 0.7 n.s.
Prosubiculum 2.2 ± 1.1 1.7 ± 0.4 2.2 ± 1.0 1.7 ± 1.2 n.s.
Subiculum 2.7 ± 1.1 2.1 ± 0.5 2.2 ± 1.3 1.1 ± 0.3 n.s.
Parasubiculum 2.7 ± 0.5 2.7 ± 0.5 2.4 ± 0.8 1.3 ± 0.5 <0.01 (MTLE groups × CTRL)
Entorhinal cortex 2.2 ± 0.5 2.4 ± 0.9 2.9 ± 1.0 1.1 ± 0.5 0.03 (MTLE + P × CTRL)
Values indicated as mean ± std. deviation. n.s.: non-significant.
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function as an endogenous mechanism counteracting
increased excitability.
A limitation of the current study is the relative hetero-
geneity of psychiatric groups. We were not able to deter-
mine quantitative details of depressive and psychotic
symptoms such as precise number and duration of epi-
sodes, although all patients in MTLE +D and MTLE + P
groups had a lifetime history of their respective psychiatric
comorbidity. There are few studies examining neuro-
pathological correlates in the hippocampus of patientswith epilepsy and psychiatric comorbidities, and more
detailed studies using psychometric scales are still needed.
Also, in spite of the fact that we could not perform stereo-
logical counts due to limited tissue source from surgery,
our neuron density numbers are in agreement with recent
hippocampal stereological counts performed in MTLE
specimens [72]. In fact, since all MTLE surgical specimens
were submitted to identical processing, differences among
them are particularly relevant. As with any human study,
assumptions must be considered when interpreting our
results. Receptor expression does not necessarily equal
Kandratavicius et al. Acta Neuropathologica Communications 2014, 2:81 Page 15 of 17
http://www.actaneurocomms.org/content/2/1/81functional activity, but given our results and evidences in
the literature we assumed that such a relationship could
exist in some circumstances. Despite our relatively small
sample size, other studies exploring neuropathological
aspects of different psychiatric comorbidities of epilepsy
have been using even smaller series [73,74], and our
results are in agreement with the recent NT receptors’
literature.
Conclusion
Our previous studies [7-9] together with the present
results demonstrate that there is an overall structural
abnormality and alterations in expression of NTs and
their receptors in the epileptogenic hippocampus, that
are differentially modulated in presence of psychiatric
comorbidities. The clinical significance of these alterations
is yet being established. NTs and their receptors are able
to regulate central neurotransmission and promote neu-
roplasticity, representing a promising study area for the
development of new treatment strategies, clearly needed
in face of different clinical symptoms and differentially
affected neuropathological substrates.
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